Illustrative image – not actual.Sandoz, the generics division of Novartis India, inaugurated its third manufacturing plant at Kalwe near Mumbai.
The new unit with an annual production capacity of one billion tablets and capsules, entailed an investment of around $13 million (approx Rs.59 crore). Full scale commercial operations are likely to begin next month. The plant is in the process of getting regulatory approvals from the US and European authorities.
The new facility is part of its $80 million (approx.Rs.365 crore) global expansion of its production network -- with three new plants this month in Poland, India and Romania.
It may be noted that the Novratis already operates two units -- at Kolshet in Thane and Turbhe in Navi Mumbai. The Kolshet unit is a development centre for finished dosage forms (FDFs) and active pharmaceutical ingredients (APIs) while the Turbhe unit is dedicated to manufacture of oral cephalosporins for all regulated and non regulated markets.
